VACCINEX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Published: 2022-01-26 08:03:07 ET VCNX

Item 8.01 Other Events.

On January 26, 2022, Vaccinex, Inc. (the "Company") issued a press release announcing interim response data in the Company's Phase 1b segment of the KEYNOTE-B84 study of Vaccinex's pepinemab in combination with Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are filed herewith:

--------------------------------------------------------------------------------